NL301057I2 - Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout - Google Patents

Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout Download PDF

Info

Publication number: NL301057I2
Authority: NL; Netherlands
Prior art keywords: degib; optionally; glass; pharmaceutically acceptable; salt
Prior art date: 2007-06-29

Application number

NL301057C

Other languages

English (en)

Other versions

NL301057I1 (nl

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-29

Filing date

2020-07-15

Publication date

2020-09-10

2020-07-15 Application filed by Pfizer filed Critical Pfizer

2020-07-22 Publication of NL301057I1 publication Critical patent/NL301057I1/nl

2020-09-10 Publication of NL301057I2 publication Critical patent/NL301057I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL301057C 2007-06-29 2020-07-15 Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout NL301057I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94728707P	2007-06-29	2007-06-29
US4164508P	2008-04-02	2008-04-02
PCT/IB2008/001575 WO2009004427A2 (en)	2007-06-29	2008-06-16	Benzimidazole derivatives

Publications (2)

Publication Number	Publication Date
NL301057I1 NL301057I1 (nl)	2020-07-22
NL301057I2 true NL301057I2 (nl)	2020-09-10

Family

ID=40161351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301057C NL301057I2 (nl)	2007-06-29	2020-07-15	Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout

Country Status (46)

Country	Link
US (2)	US8148401B2 (nl)
EP (1)	EP2170860B9 (nl)
JP (2)	JP4567099B2 (nl)
KR (1)	KR101143246B1 (nl)
CN (1)	CN101687841B (nl)
AP (1)	AP2377A (nl)
AR (1)	AR067346A1 (nl)
AU (1)	AU2008272641B2 (nl)
BR (1)	BRPI0813412B8 (nl)
CA (1)	CA2690953C (nl)
CL (1)	CL2008001922A1 (nl)
CO (1)	CO6160232A2 (nl)
CR (1)	CR11150A (nl)
CU (1)	CU23847B1 (nl)
CY (2)	CY1118650T1 (nl)
DK (1)	DK2170860T5 (nl)
DO (1)	DOP2009000278A (nl)
EA (1)	EA016888B1 (nl)
EC (1)	ECSP099803A (nl)
ES (1)	ES2609258T3 (nl)
FR (1)	FR20C1038I2 (nl)
GE (1)	GEP20125702B (nl)
GT (1)	GT200900328A (nl)
HK (1)	HK1139658A1 (nl)
HN (1)	HN2008000974A (nl)
HR (1)	HRP20161562T2 (nl)
HU (2)	HUE030052T4 (nl)
IL (1)	IL202420A (nl)
LT (2)	LT2170860T (nl)
MA (1)	MA31466B1 (nl)
ME (1)	ME00962B (nl)
MY (1)	MY148636A (nl)
NI (1)	NI200900219A (nl)
NL (1)	NL301057I2 (nl)
NO (1)	NO2020027I1 (nl)
NZ (1)	NZ581889A (nl)
PA (1)	PA8785401A1 (nl)
PE (2)	PE20121010A1 (nl)
PL (1)	PL2170860T3 (nl)
PT (1)	PT2170860T (nl)
RS (1)	RS55395B9 (nl)
SI (1)	SI2170860T1 (nl)
TN (1)	TN2009000544A1 (nl)
TW (1)	TWI371451B (nl)
UY (1)	UY31164A1 (nl)
WO (1)	WO2009004427A2 (nl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP20125702B (en) *	2007-06-29	2012-12-10	Pfizer	Benzimidazole derivatives
CA2735593C (en)	2008-09-03	2017-08-15	Repligen Corporation	Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
EP2440544B1 (en) *	2009-06-11	2013-08-14	Siena Biotech S.p.A.	Hedgehog pathway antagonists and therapeutic applications thereof
WO2011024872A1 (ja)	2009-08-26	2011-03-03	武田薬品工業株式会社	縮合複素環誘導体およびその用途
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US9056865B2 (en)	2010-10-20	2015-06-16	Pfizer Inc.	Pyridine-2-derivatives as smoothened receptor modulators
JP5452459B2 (ja)	2010-12-16	2014-03-26	株式会社Ｎｔｔドコモ	ホーム基地局及びハンドオーバ方法
CA3061239A1 (en)	2011-02-28	2012-09-07	Biomarin Pharmaceutical Inc.	Histone deacetylase inhibitors
US8957066B2 (en)	2011-02-28	2015-02-17	Biomarin Pharmaceutical Inc.	Histone deacetylase inhibitors
US10059723B2 (en)	2011-02-28	2018-08-28	Biomarin Pharmaceutical Inc.	Histone deacetylase inhibitors
EP2684167B1 (en) *	2011-03-08	2020-09-09	Eutropics Pharmaceuticals, Inc.	Compositions and methods useful for treating diseases
FR2980477B1 (fr)	2011-09-23	2013-10-18	Centre Nat Rech Scient	Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
AU2012314943B9 (en)	2011-09-26	2017-06-08	Merck Patent Gmbh	Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
US20150133450A1 (en)	2012-06-20	2015-05-14	Eutropics Pharmaceuticals, Inc.	Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en)	2012-11-21	2016-02-11	David Richard	Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
RU2665554C2 (ru)	2013-03-15	2018-08-31	Байомарин Фармасьютикал Инк.	Ингибиторы hdac
WO2014170350A1 (en) *	2013-04-17	2014-10-23	Albert Ludwigs Universität Freiburg	Compounds for use as bromodomain inhibitors
US10732182B2 (en)	2013-08-01	2020-08-04	Eutropics Pharmaceuticals, Inc.	Method for predicting cancer sensitivity
GB2519344A (en) *	2013-10-18	2015-04-22	Redx Pharma Ltd	Compounds
US10640803B2 (en)	2013-10-30	2020-05-05	Eutropics Pharmaceuticals, Inc.	Methods for determining chemosensitivity and chemotoxicity
HUE059506T2 (hu) *	2015-04-24	2022-11-28	Pfizer	Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
JP2020164722A (ja) *	2019-03-29	2020-10-08	デクセリアルズ株式会社	接着剤組成物
EP4097093B8 (en)	2020-01-28	2024-02-28	Assia Chemical Industries LTD	Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN113248475B (zh) *	2020-02-11	2023-03-17	中国科学院上海药物研究所	一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (en)	2020-03-26	2024-04-10	LEK Pharmaceuticals d.d.	Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
CN115997122A (zh)	2020-06-26	2023-04-21	拉夸里亚创药株式会社	类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
WO2023002362A1 (en)	2021-07-22	2023-01-26	Pfizer Inc.	Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4658473B2 (ja) *	2001-07-27	2011-03-23	キュリス，インコーポレイテッド	ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
EP1499607B1 (en) *	2001-12-04	2005-12-07	Actelion Pharmaceuticals Ltd.	4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
TW200304820A (en)	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
AU2003301436A1 (en) *	2002-10-17	2004-05-04	Amgen Inc.	Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2005042495A1 (en)	2003-10-21	2005-05-12	Imclone Systems Incorporated	(benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
JP2007521325A (ja)	2003-10-28	2007-08-02	バーテックス　ファーマシューティカルズ　インコーポレイテッド	イオンチャネルのモジュレーターとして有用なベンズイミダゾール
NZ555419A (en) *	2004-11-03	2009-07-31	Curis Inc	Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) *	2005-03-19	2006-11-16	Sanofi-Aventis Deutschland Gmbh	Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) *	2005-05-12	2006-11-23	Kalypsys, Inc.	Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en)	2006-11-27	2008-06-05	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
CA2672815A1 (en)	2006-12-15	2008-06-26	Pfizer Products Inc.	Benzimidazole derivatives for use in treating abnormal cell growth
GEP20125702B (en) *	2007-06-29	2012-12-10	Pfizer	Benzimidazole derivatives
EP2303275A4 (en)	2008-06-17	2012-05-09	Univ Duke	STANDARD RECEPTOR MODULATORS
ES2797955T3 (es)	2008-08-25	2020-12-04	Novartis Ag	Moduladores de la ruta de hedgehog

2008
- 2008-06-16 GE GEAP200811622A patent/GEP20125702B/en unknown
- 2008-06-16 EP EP08762901.0A patent/EP2170860B9/en active Active
- 2008-06-16 WO PCT/IB2008/001575 patent/WO2009004427A2/en active Application Filing
- 2008-06-16 JP JP2010514162A patent/JP4567099B2/ja active Active
- 2008-06-16 AP AP2009005089A patent/AP2377A/xx active
- 2008-06-16 DK DK08762901.0T patent/DK2170860T5/en active
- 2008-06-16 ME MEP-2009-349A patent/ME00962B/me unknown
- 2008-06-16 CA CA2690953A patent/CA2690953C/en active Active
- 2008-06-16 HU HUE08762901A patent/HUE030052T4/en unknown
- 2008-06-16 KR KR1020107001991A patent/KR101143246B1/ko active IP Right Grant
- 2008-06-16 MY MYPI20095266A patent/MY148636A/en unknown
- 2008-06-16 RS RS20161132A patent/RS55395B9/sr unknown
- 2008-06-16 LT LTEP08762901.0T patent/LT2170860T/lt unknown
- 2008-06-16 SI SI200831707A patent/SI2170860T1/sl unknown
- 2008-06-16 EA EA200971104A patent/EA016888B1/ru unknown
- 2008-06-16 BR BRPI0813412A patent/BRPI0813412B8/pt active IP Right Grant
- 2008-06-16 PT PT87629010T patent/PT2170860T/pt unknown
- 2008-06-16 NZ NZ581889A patent/NZ581889A/en unknown
- 2008-06-16 CN CN200880022602XA patent/CN101687841B/zh active Active
- 2008-06-16 ES ES08762901.0T patent/ES2609258T3/es active Active
- 2008-06-16 PL PL08762901T patent/PL2170860T3/pl unknown
- 2008-06-16 AU AU2008272641A patent/AU2008272641B2/en active Active
- 2008-06-19 PA PA20088785401A patent/PA8785401A1/es unknown
- 2008-06-19 US US12/142,119 patent/US8148401B2/en active Active
- 2008-06-20 UY UY31164A patent/UY31164A1/es active IP Right Grant
- 2008-06-25 HN HN2008000974A patent/HN2008000974A/es unknown
- 2008-06-27 PE PE2012000473A patent/PE20121010A1/es active IP Right Grant
- 2008-06-27 TW TW097124392A patent/TWI371451B/zh active
- 2008-06-27 AR ARP080102792A patent/AR067346A1/es active IP Right Grant
- 2008-06-27 PE PE2008001105A patent/PE20090772A1/es active IP Right Grant
- 2008-06-27 CL CL2008001922A patent/CL2008001922A1/es unknown
2009
- 2009-11-30 IL IL202420A patent/IL202420A/en active IP Right Grant
- 2009-12-07 CR CR11150A patent/CR11150A/es unknown
- 2009-12-08 DO DO2009000278A patent/DOP2009000278A/es unknown
- 2009-12-14 EC EC2009009803A patent/ECSP099803A/es unknown
- 2009-12-18 NI NI200900219A patent/NI200900219A/es unknown
- 2009-12-21 GT GT200900328A patent/GT200900328A/es unknown
- 2009-12-21 CU CU2009000225A patent/CU23847B1/es active IP Right Grant
- 2009-12-23 CO CO09147462A patent/CO6160232A2/es unknown
- 2009-12-25 TN TNP2009000544A patent/TN2009000544A1/fr unknown
- 2009-12-29 MA MA32454A patent/MA31466B1/fr unknown
2010
- 2010-06-09 HK HK10105659.9A patent/HK1139658A1/xx unknown
- 2010-08-04 JP JP2010175465A patent/JP2010280693A/ja active Pending
2012
- 2012-02-24 US US13/404,169 patent/US8431597B2/en active Active
2016
- 2016-11-23 HR HRP20161562TT patent/HRP20161562T2/hr unknown
- 2016-12-14 CY CY20161101293T patent/CY1118650T1/el unknown
2020
- 2020-07-15 NL NL301057C patent/NL301057I2/nl unknown
- 2020-08-11 NO NO2020027C patent/NO2020027I1/no unknown
- 2020-08-12 CY CY2020028C patent/CY2020028I2/el unknown
- 2020-08-13 HU HUS2000031C patent/HUS2000031I1/hu unknown
- 2020-08-20 FR FR20C1038C patent/FR20C1038I2/fr active Active
- 2020-08-26 LT LTPA2020528C patent/LTC2170860I2/lt unknown

Also Published As

Publication number	Publication date
MA31466B1 (fr)	2010-06-01
SI2170860T1 (sl)	2017-01-31
HK1139658A1 (en)	2010-09-24
UY31164A1 (es)	2009-01-30
ME00962B (me)	2012-06-20
EA016888B1 (ru)	2012-08-30
DOP2009000278A (es)	2009-12-31
AR067346A1 (es)	2009-10-07
IL202420A (en)	2014-05-28
FR20C1038I1 (nl)	2020-10-02
BRPI0813412B8 (pt)	2021-05-25
ECSP099803A (es)	2010-01-29
AP2009005089A0 (en)	2009-12-31
WO2009004427A3 (en)	2009-06-04
CY2020028I1 (el)	2020-11-25
NO2020027I1 (no)	2020-08-11
TW200911792A (en)	2009-03-16
PL2170860T3 (pl)	2017-05-31
JP2010531869A (ja)	2010-09-30
HUE030052T2 (hu)	2017-04-28
CU20090225A7 (es)	2012-02-15
US8148401B2 (en)	2012-04-03
JP2010280693A (ja)	2010-12-16
CA2690953A1 (en)	2009-01-08
DK2170860T5 (en)	2017-03-20
PT2170860T (pt)	2017-01-04
CR11150A (es)	2010-02-08
JP4567099B2 (ja)	2010-10-20
PE20121010A1 (es)	2012-08-06
HRP20161562T2 (hr)	2017-04-21
EA200971104A1 (ru)	2010-06-30
RS55395B1 (sr)	2017-04-28
LTC2170860I2 (lt)	2022-03-10
CL2008001922A1 (es)	2009-01-02
HN2008000974A (es)	2011-01-24
DK2170860T3 (en)	2017-01-09
TN2009000544A1 (fr)	2011-03-31
AP2377A (en)	2012-03-07
CN101687841B (zh)	2013-07-10
AU2008272641B2 (en)	2013-08-29
HRP20161562T1 (hr)	2016-12-30
WO2009004427A2 (en)	2009-01-08
LT2170860T (lt)	2017-01-10
HUS2000031I1 (hu)	2020-09-28
EP2170860B9 (en)	2017-02-22
ES2609258T3 (es)	2017-04-19
IL202420A0 (en)	2010-06-30
NZ581889A (en)	2011-05-27
NL301057I1 (nl)	2020-07-22
BRPI0813412B1 (pt)	2020-01-21
CA2690953C (en)	2012-10-02
MY148636A (en)	2013-05-15
CY1118650T1 (el)	2017-07-12
KR20100028120A (ko)	2010-03-11
CN101687841A (zh)	2010-03-31
TWI371451B (en)	2012-09-01
BRPI0813412A2 (pt)	2014-12-30
KR101143246B1 (ko)	2012-05-18
US20090005416A1 (en)	2009-01-01
US20120157495A1 (en)	2012-06-21
LTPA2020528I1 (lt)	2020-09-25
CY2020028I2 (el)	2020-11-25
GT200900328A (es)	2011-08-29
CU23847B1 (es)	2012-10-15
EP2170860A2 (en)	2010-04-07
EP2170860B1 (en)	2016-11-02
NI200900219A (es)	2010-03-11
PE20090772A1 (es)	2009-06-24
US8431597B2 (en)	2013-04-30
FR20C1038I2 (fr)	2021-08-13
AU2008272641A1 (en)	2009-01-08
HUE030052T4 (en)	2017-06-28
GEP20125702B (en)	2012-12-10
PA8785401A1 (es)	2009-01-23
RS55395B9 (sr)	2020-01-31
CO6160232A2 (es)	2010-05-20

Publication	Publication Date	Title
NL301057I1 (nl)	2020-07-22	Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301150I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl)	2020-07-01	Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301033I2 (nl)	2020-04-15	Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL301199I2 (nl)	2023-02-16	Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301021I2 (nl)	2020-04-14	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl)	2020-06-17	Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301230I2 (nl)	2023-07-26	Mitapivat, dan wel een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder mitapivatsulfaat
NL300971I2 (nl)	2019-04-11	Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301041I2 (nl)	2020-09-14	Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301261I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL350110I2 (nl)	2023-10-04	Oxathiapiproline, desgewenst in de vorm van het N-oxide ervan of een zout ervan, en amisulbrom
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301209I1 (nl)	2022-12-21	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL300946I2 (nl)	2018-09-26	Brexpiprazole, desgewenst in de vorm van een zout
HUS000509I2 (hu)	2021-03-29	Abemaciklib vagy egy gyógyászatilag elfogadható sója
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL300937I2 (nl)	2019-01-08	Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan